Regorafenib

BNF:: 8.1.5
Status:: Do Not Prescribe (DNP), Red
Decision Date:: March 2015

Comments

DO NOT PRESCRIBE (DNP):

NICE TA334 - terminated appraisal
NICE TA514 - regorafenib for previously treated advanced hepatocellular carcinoma. (Decision date - April 2018)

RED:

NICE TA488 - for previously treated unresectable or metastatic gastrointestinal stromal tumours. (Decision date - December 2017)
NICE TA555 - previously treated advanced hepatocellular carcinoma. (Decision date - February 2019)
NICE TA866 - for previously treated metastatic colorectal cancer. (Decision date - March 2023)

Black Drug Classifications

6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)